The randomised, double-blind, placebo-controlled WILLOW study (NCT05162586) was investigating the therapy in 456 patients ...

SLE: Systemic lupus erythematosus ... are being tapered there is often a major risk for relapse if no other therapy is initiated. Therefore, many clinicians will start longer-term, maintenance ...

Current treatments for systemic lupus erythematosus (SLE) and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis include toxic immunosuppressive agents such as cyclophosphamide, and ...

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) ...

Belimumab combined with standard therapy demonstrated significant improvements in mucocutaneous symptoms in patients with systemic lupus erythematosus (SLE) compared with placebo with standard ...